Vial

Global Markets for Emerging Insulin Drug and Delivery Technologies, with Focus on Syringes and Vials - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Diabetes, Pharmaceutical, Health, Medical Supplies, Diagnosis, Cardiovascular disease, Prevalence, Disease, Insulin, ESG, Peripheral neuropathy, Syringe, Paratriathlon, Vial, Delivery, Pharmaceutical industry

The "Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials" report has been added to ResearchAndMarkets.com's offering.
  • This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies.
  • Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.
  • The market for insulin drug and delivery technologies will continue to grow significantly in many areas, notably regulatory compliance.

Resilience Expands Clinical and Commercial Drug Product Manufacturing Capabilities and Capacities

Retrieved on: 
Tuesday, February 20, 2024
Chemicals, Plastics, Health, Manufacturing, Other Health, Pharmaceutical, Biotechnology, FDA, Vial, Cartridge, PFS, History, RTP, Gene, Pharmaceutical industry

National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network.

Key Points: 
  • National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network.
  • Resilience’s pre-clinical, clinical and commercial cGMP manufacturing network was built to help withstand unforeseen difficulties like capacity constraints, raw material supply chain shortages and disruptions.
  • Additionally, Resilience is expanding its drug product capabilities at the company’s RTP facility in North Carolina using a modular design within its segregated expansion space to offer drug product manufacturing for multiple modalities.
  • “Strengthening our drug product manufacturing capacity across the Resilience network highlights our commitment to providing robust and scalable outsourcing options for our partners,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.

EQS-News: Successful Operation of a Large-scale Energy Storage System by ADS-TEC Energy in Switzerland

Retrieved on: 
Saturday, December 30, 2023
Plant, Digital, Vial, Partnership, Domat/Ems

Since 2021, a high-performance energy storage system from ADS-TEC Energy has been operating at the energy provider Rhiienergie AG in Graubünden, Switzerland.

Key Points: 
  • Since 2021, a high-performance energy storage system from ADS-TEC Energy has been operating at the energy provider Rhiienergie AG in Graubünden, Switzerland.
  • Rhiienergie is consistently impressed by the performance and reliability of the system and values its partnership with ADS-TEC Energy.
  • NÜRTINGEN, Germany – November 15, 2023 – For over a decade, ADS-TEC Energy (NASDAQ: ADSE), a global leader in battery-buffered platform solutions, has delivered large-scale battery energy storage plants in the megawatt range with the flexibility required for energy transition.
  • High-performance energy storage system from ADS-TEC Energy has been operating at the energy provider Rhiienergie AG in Graubünden, Switzerland
    Since March 26, 2021, a large-scale energy storage system with a capacity of 1.25 megawatts and 1.3 megawatt-hours has been operational for Rhiienergie AG in Graubünden, Switzerland.

Successful Operation of a Large-scale Energy Storage System by ADS-TEC Energy in Switzerland

Retrieved on: 
Wednesday, November 15, 2023
Environment, Technology, EV, Electric Vehicles, Automotive, Alternative Energy, Sustainability, Green Technology, Energy, Batteries, Domat/Ems, Digital, Vial, Multimedia, Plant, Cryptocurrency, Renewable energy, Electric power

For over a decade, ADS-TEC Energy (NASDAQ: ADSE), a global leader in battery-buffered platform solutions, has delivered large-scale battery energy storage plants in the megawatt range with the flexibility required for energy transition.

Key Points: 
  • For over a decade, ADS-TEC Energy (NASDAQ: ADSE), a global leader in battery-buffered platform solutions, has delivered large-scale battery energy storage plants in the megawatt range with the flexibility required for energy transition.
  • As a system provider with in-house developed battery technology, including battery management and control, the company has a long history in large-scale storage solutions.
  • View the full release here: https://www.businesswire.com/news/home/20231115071212/en/
    ADS-TEC Energy's high-performance energy storage system at the energy provider Rhiienergie in Switzerland has paid for itself in just two years (Photo: Business Wire)
    Since March 26, 2021, a large-scale energy storage system with a capacity of 1.25 megawatts and 1.3 megawatt-hours has been operational for Rhiienergie AG in Graubünden, Switzerland.
  • Digital twins are created for the entire system down to the cell level and each storage unit is monitored by ADS-TEC Energy through a secure connection to detect critical system conditions in a timely manner.

Vial Announces Collaborative Alliance with Mason

Retrieved on: 
Wednesday, November 15, 2023
SAN, ESourcing Capability Model, Entrepreneurship, Clinical trial, Tablet, Patient, Clinical data management, Data collection, EDC, Digital technology, Partnership, Mason, Pharmaceutical industry, Vaccine, Vial

As part of the collaboration, Mason will provide Vial with hardware as a service for clinical sites, enabling remote management of devices for eSource at a global scale.

Key Points: 
  • As part of the collaboration, Mason will provide Vial with hardware as a service for clinical sites, enabling remote management of devices for eSource at a global scale.
  • This partnership empowers Vial to focus on accelerating the development of new therapies and devices for its sponsors and patients.
  • Mason, founded by President Jim Xiao, is enthusiastic about joining forces with Vial in this venture.
  • The collaboration between Vial and Mason has already yielded significant results, with Mason's tablets successfully deployed to clinical trial sites across the United States.

West to Attend and Showcase Industry Leadership in Packaging and Containment at CPHI Worldwide Conference

Retrieved on: 
Monday, October 23, 2023
Sustainability, NYSE, West Pharmaceutical Services, WST, Vial, Control, Development, Containment, Drug delivery, Renewable energy, Fine chemical

EXTON, Pa., Oct. 23, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPHI Worldwide in Barcelona, Spain to showcase its leadership and expertise on industry challenges and trends in packaging and containment.

Key Points: 
  • EXTON, Pa., Oct. 23, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPHI Worldwide in Barcelona, Spain to showcase its leadership and expertise on industry challenges and trends in packaging and containment.
  • "West is applying its 100 years of innovation to address the changing containment and delivery needs of more complex molecules and combination products as well as more sustainable options for the industry," said Chris Ryan, Vice President, Containment and Glass Systems at West.
  • "At this year's CPHI, West will be sharing our guidance on Annex 1 EU GMP regulations and, as the exclusive distributor of Corning® Viridian™ Vials, we will be introducing this product that brings both performance and sustainability to the industry."
  • For more information about West, please visit our website: www.westpharma.com .

Vial Announces October Session of "First in Human: The Panel Series" Featuring Esteemed Panelists Jen Watts, Dr. Raj Agrawal, and Bruno Gagnon

Retrieved on: 
Monday, October 2, 2023
PST, Knowledge, Vial, Ophthalmology, Senior, SAN, Contract research organization, Tutoring

The upcoming October session is set to take place as a live roundtable discussion and is scheduled for Wednesday, October 25, 2023, *at 8:00 AM (PST).

Key Points: 
  • The upcoming October session is set to take place as a live roundtable discussion and is scheduled for Wednesday, October 25, 2023, *at 8:00 AM (PST).
  • This session centers around the topic of "Navigating the Ophthalmology Clinical Operations Landscape: Insights for Advancement."
  • Hosted by Bruno Gagnon , Senior Vice President of Global Clinical Operations at Opthea, the 60-minute panel session will feature a lineup of esteemed biotech experts.
  • "We are thrilled to continue our Panel Series with this exciting October session," said Catie Neel, Director of Events and Public Relations at Vial.

Nexus Pharmaceuticals Receives FDA Approval for Fluorescein Injection, USP

Retrieved on: 
Tuesday, September 26, 2023
Other Manufacturing, FDA, Manufacturing, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Nexus, Medication, Food and Drug Administration, Vial, USP, Food, Pharmaceutical industry

Nexus Pharmaceuticals, LLC announced it has received U.S. Food and Drug Administration (FDA) approval for Fluorescein Injection, USP.

Key Points: 
  • Nexus Pharmaceuticals, LLC announced it has received U.S. Food and Drug Administration (FDA) approval for Fluorescein Injection, USP.
  • “Receiving FDA approval for Fluorescein Injection is another exciting step made towards addressing a supply shortfall of a critical medication on the FDA drug shortage list,” said Usman Ahmed, President and Chief Executive Officer.
  • “Nexus stands ready to continue to be part of the solution in the battle against drug shortages.”
    Nexus Pharmaceuticals’ Fluorescein Injection, USP 10% is available in cartons of ten 5 mL Single-dose Vials.

Vial to Sponsor the 21st Precision in Clinical Trials Summit 2023 in San Diego, CA

Retrieved on: 
Monday, September 25, 2023
PST, Clinical trial, Business development, Piz Vial, Business, SAN, Sales, Pharmaceutical industry, Vaccine, Vial

SAN FRANCISCO, Sept. 24, 2023 /PRNewswire/ -- Vial , a global full-service CRO providing tech-forward clinical trial management services, announced its participation as a sponsor, exhibitor, and speaker at the 21st Precision in Clinical Trials Summit, taking place in San Diego, CA, on October 16-17, 2023, at the Westin San Diego Bayview.

Key Points: 
  • SAN FRANCISCO, Sept. 24, 2023 /PRNewswire/ -- Vial , a global full-service CRO providing tech-forward clinical trial management services, announced its participation as a sponsor, exhibitor, and speaker at the 21st Precision in Clinical Trials Summit, taking place in San Diego, CA, on October 16-17, 2023, at the Westin San Diego Bayview.
  • Attendees can look forward to an innovation-focused agenda, pre-scheduled meetings between potential collaborators, and access to a wide array of reliable solution providers.
  • The summit is poised to provide attendees with the means to address their most pressing clinical trial challenges both in 2023 and beyond.
  • How to connect with Vial at the 21st Precision in Clinical Trials Summit?

Vial to Sponsor the 4th Annual Gene Therapy for Ophthalmic Disorders Conference 2023 in Boston, MA

Retrieved on: 
Wednesday, September 20, 2023
Vial, Business development, Business, Conference, SAN, Ophthalmology, Pharmaceutical industry

SAN FRANCISCO, Sept. 19, 2023 /PRNewswire/ -- Vial , a global full-service CRO providing tech-forward clinical trial management services, announced its participation as a sponsor and speaker at the 4th Annual Gene Therapy for Ophthalmic Disorders Conference in Boston, MA, October 3-5, 2023, at the Hilton Boston Back Bay.

Key Points: 
  • SAN FRANCISCO, Sept. 19, 2023 /PRNewswire/ -- Vial , a global full-service CRO providing tech-forward clinical trial management services, announced its participation as a sponsor and speaker at the 4th Annual Gene Therapy for Ophthalmic Disorders Conference in Boston, MA, October 3-5, 2023, at the Hilton Boston Back Bay.
  • The 4th Annual Gene Therapy for Ophthalmic Disorders Conference is a preeminent event that unites thought leaders from leading biopharma, biotech, and academic institutes working to transform eye disease treatment.
  • "I am genuinely grateful for the invitation and excited about the prospect of meaningful conversations that could shape the trajectory of gene therapy for ophthalmic disorders.
  • How to connect with Vial at the 4th Annual Gene Therapy for Ophthalmic Disorders Conference?